Vernon Steele

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Potential use of lipoxygenase inhibitors for cancer chemoprevention
    V E Steele
    Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA
    Expert Opin Investig Drugs 9:2121-38. 2000
  2. ncbi Correlation between electron-donating ability of a series of 3-nitroflavones and their efficacy to inhibit the onset and progression of aberrant crypt foci in the rat colon
    Vernon E Steele
    Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, Maryland 20892 7322, USA
    Cancer Res 62:6506-9. 2002
  3. ncbi Development of cancer chemopreventive drugs based on mechanistic approaches
    Vernon E Steele
    National Cancer Institute, EPN 2108, MSC 7322, 9000 Rockville Pike, National Institutes of Health, Bethesda, MD 20892 7322, USA
    Mutat Res 591:16-23. 2005
  4. ncbi Comparative effects of DHEA and DHT on gene expression in human LNCaP prostate cancer cells
    Vernon E Steele
    Endocrine Section, Laboratory of Clinical Investigation, Division of Intramural Research, National Center for Complementary and Alternative Medicine, National Institutes of Health, Bethesda, MD 20892, USA
    Anticancer Res 26:3205-15. 2006
  5. ncbi The use of animal models for cancer chemoprevention drug development
    Vernon E Steele
    Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, MD, USA
    Semin Oncol 37:327-38. 2010
  6. ncbi Dehydroepiandrosterone inhibits the progression phase of mammary carcinogenesis by inducing cellular senescence via a p16-dependent but p53-independent mechanism
    Anne Shilkaitis
    Department of Surgical Oncology, University of Illinois, 840 S, Wood Str, Chicago, IL 60612, USA
    Breast Cancer Res 7:R1132-40. 2005
  7. ncbi Challenges in clinical prostate cancer: role of imaging
    Gary J Kelloff
    Division of Cancer Treatment and Diagnosis, Cancer Imaging Program, National Institutes of Health, National Cancer Institute, Bethesda, MD 20852, USA
    AJR Am J Roentgenol 192:1455-70. 2009

Detail Information

Publications7

  1. ncbi Potential use of lipoxygenase inhibitors for cancer chemoprevention
    V E Steele
    Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA
    Expert Opin Investig Drugs 9:2121-38. 2000
    ..Based on currently available data, it is expected that the prevention of lung and prostate cancer will be initially studied in human trials of LO inhibitors...
  2. ncbi Correlation between electron-donating ability of a series of 3-nitroflavones and their efficacy to inhibit the onset and progression of aberrant crypt foci in the rat colon
    Vernon E Steele
    Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, Maryland 20892 7322, USA
    Cancer Res 62:6506-9. 2002
    ..The above correlations may be of predictive value in the search for new chemoprotective agents. The overall molecular mechanism of the inhibition of ACF by the 3-nitroflavones under study appears to involve redox reactions...
  3. ncbi Development of cancer chemopreventive drugs based on mechanistic approaches
    Vernon E Steele
    National Cancer Institute, EPN 2108, MSC 7322, 9000 Rockville Pike, National Institutes of Health, Bethesda, MD 20892 7322, USA
    Mutat Res 591:16-23. 2005
    ..Each cancer type, organ location, or individual genetic background may require a custom combination of prevention strategies to be successful...
  4. ncbi Comparative effects of DHEA and DHT on gene expression in human LNCaP prostate cancer cells
    Vernon E Steele
    Endocrine Section, Laboratory of Clinical Investigation, Division of Intramural Research, National Center for Complementary and Alternative Medicine, National Institutes of Health, Bethesda, MD 20892, USA
    Anticancer Res 26:3205-15. 2006
    ..Because DHEA can be converted to androgens or estrogens, such use may promote prostate cancer. In this study, the effects of DHEA were compared with those of DHT using gene expression array profiles in human LNCaP prostate cancer cells...
  5. ncbi The use of animal models for cancer chemoprevention drug development
    Vernon E Steele
    Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, MD, USA
    Semin Oncol 37:327-38. 2010
    ..Whether validated or not, animal efficacy data remain central to the clinical trial decision-making process...
  6. ncbi Dehydroepiandrosterone inhibits the progression phase of mammary carcinogenesis by inducing cellular senescence via a p16-dependent but p53-independent mechanism
    Anne Shilkaitis
    Department of Surgical Oncology, University of Illinois, 840 S, Wood Str, Chicago, IL 60612, USA
    Breast Cancer Res 7:R1132-40. 2005
    ..Here we examine whether DHEA and its analog DHEA 8354 can suppress the progression of hyperplastic and premalignant (carcinoma in situ) lesions in mammary gland toward malignant tumors and the cellular mechanisms involved...
  7. ncbi Challenges in clinical prostate cancer: role of imaging
    Gary J Kelloff
    Division of Cancer Treatment and Diagnosis, Cancer Imaging Program, National Institutes of Health, National Cancer Institute, Bethesda, MD 20852, USA
    AJR Am J Roentgenol 192:1455-70. 2009
    ..The overarching issue in prostate cancer is distinguishing lethal from nonlethal disease. New technologies and fresh uses for established procedures make imaging effective in both assessing and treating prostate cancer...